Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past hour
Any time
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
47m
Why Pfizer will find it hard to appease its activist investor
The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.
7m
GSK says RSV vaccine protects against disease over three seasons
Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
North Dakota wildfires
Kemp suspends GA mayor
Milton becomes Category 5
Medical copter crash kills 3
Sex abuse case dismissed
Human life expectancy study
Harris on '60 Minutes'
Ranger dies during rescue
Tickets to climb to $5
Vanderbilt, Arkansas fined
Former aide charged
To replace lead water pipes
Hamas backers sanctioned
NC voting rule changes
King named grand marshal
Richest female musician
Grammy-winning singer dies
States sue TikTok
Liquidation plan approved
Intel defensive briefings rise
Israel expands offensive
Ordered to open app store
Win Nobel Prize in physics
US antitrust case advances
SCOTUS denies appeal
Athlete payments approval
Settles latest civil lawsuit
Hera mission launched
US overdose deaths drop
Related topics
GSK
United States
GlaxoSmithKline
Feedback